Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Status: RecruitingPhase: Phase 2Diagnosis: Breast: MetastaticNCT ID: NCT01494662
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 11-344
The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2). In this research study, the investigators are looking to see how well neratinib works to decrease the size of or stabilize breast cancer that has spread to the brain. The investigators are also looking at how previous treatments have affected your thinking (or cognition) and how much neratinib reaches the central nervous system.
Conducting Institutions: Dana-Farber Cancer Institute, Beth-Israel Deaconess Medical Center, Dana Farber Cancer Institute at Faulkner Hospital, Massachusetts General Hospital
Overall PI: Rachel Freedman, MD,
Dana Farber Cancer Institute
Site-responsible Investigators: Christina Herold,
Beth Israel Deaconess Medical CenterErica Mayer, MD,
Dana-Farber Cancer InstituteBeverly Moy, MD,
Massachusetts General Hospital
Contacts: Dana-Farber Cancer Institute:
Breast Cancer Nursing Team, 617-632-3478Beth-Israel Deaconess Medical Center:
Cancer Trials Call Center, 617-667-3060Massachusetts General Hospital:
Cancer Trials Call Center, 877-789-6100